ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 973

New Genetic Risk Loci for the Radiographic Severity of Rheumatoid Arthritis

Diederik P.C. de Rooy1, Sacha Zhernakova1, Roula Tsonaka2, Fina Kurreeman3, René E.M. Toes1, Tom W. J. Huizinga4, Jeanine Houwing-Duistermaat5, Peter K. Gregersen6 and Annette H.M. van der Helm-van Mil1, 1Rheumatology, Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Medical Statistics, Leiden University Medical Center, Leiden, Netherlands, 3Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Department of Rheumatology, Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Statistics, Statistics, Leiden University Medical Center, Leiden, Netherlands, 6Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, genomics and joint destruction

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Genetics and Genomics of Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The severity of joint destruction is highly variable between Rheumatoid Arthritis (RA) patients; approximately 54% of this variance is explained by genetic factors. Many of the genetic factors responsible for the severity of joint destruction are unknown.  We aimed to identify new genetic risk factors by studying genetic susceptibility loci of several auto-immune diseases.

Methods:

In the first phase, 646 Dutch RA-patients with yearly X-rays of hands and feet over 7 years of follow-up were studied. These patients were genotyped for 148,880 SNPs by Immunochip which contains 186 loci previously associated with autoimmune diseases. Following quality control, association of SNPs with MAF >0.01 (130,841 SNPS) with joint destruction was analyzed using a marginal regression model. Correction for multiple testing was done using the Bonferroni correction for the number of uncorrelated SNPs (threshold p<1.1x10-6). In the second phase, 686 North American RA-patients with repeated hands X-rays over 15 years of follow-up, for which Immunochip genotyping data were also available, were studied. SNPs that were significantly associated in phase 1 were selected and evaluated. All X-rays were scored by the Sharp van der Heijde score (ICC 0.91 and 0.98 for phase 1 and 2 respectively).

Results:

In phase 1, 109 SNPs were significantly associated with joint destruction in Dutch RA-patients (threshold p<1.1x10-6). Of these, 76 were located in the HLA-region in chromosome 6; since the association of this region with joint damage is already known, these SNPs were not analyzed in phase 2. The other 33 non-HLA genetic variants, though several were in high LD, were studied in the North-American RA-patients. After correction for the number of number of uncorrelated SNPs (threshold p<0.0036), two variants were associated with the severity of joint destruction. These were rs451066 on chromosome 14 (puncorrected=0.002, MAF=0.20)) and rs11908352 on chromosome 20 (puncorrected=0.002, MAF=0.21). In the presence of a risk allele of rs451066 and rs11908352 respectively Dutch RA-patients had a 3.7% and 2.7% higher rate of joint destruction per year, which equals 29% and 20% more joint destruction over a seven years period.

Conclusion:

Two new risk loci for progressive joint destruction in RA were identified. The region of rs451066 on chromosome 14 has previously been linked to susceptibility to type-1 diabetes. The other SNP is located at chromosome 20 and in low LD with rs4810485 (R2 0.062), a variant that has previously been identified as RA risk locus. Altogether, the current data indicate that two loci that confer risk to other autoimmune disease may also affect the severity of RA.


Disclosure:

D. P. C. de Rooy,
None;

S. Zhernakova,
None;

R. Tsonaka,
None;

F. Kurreeman,
None;

R. E. M. Toes,
None;

T. W. J. Huizinga,
None;

J. Houwing-Duistermaat,
None;

P. K. Gregersen,
None;

A. H. M. van der Helm-van Mil,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/new-genetic-risk-loci-for-the-radiographic-severity-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology